NCT07135102招募中1 期
A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer
Xiaorong Sun1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2024年10月14日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Treatment emergent adverse events
研究概览
简要总结
The purpose of this study is to determine the safety and efficacy of 225Ac -labeled PSMA ligand(PSMA-XT) in the treatment of mCRPC
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •have the ability to understand and sign an approved informed consent form (ICF).
- •>= 18 years old.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •have a life expectancy >6 months.
- •have histological, pathological, and/or cytological confirmation of prostate cancer.
- •PSMA Positron Emission Tomography (PET)/Computed Tomography (CT) scan positive
- •have a castrate level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L).
- •have received at least one NAAD (such as enzalutamide and/or abiraterone)； patients must have been previously treated undergone at least 1-2 prior taxane-based chemotherapy regimens or be unsuitable for taxane therapy (unsuitability includes contraindications, investigator-determined ineligibility, or patient refusal) in mCRPC stage.
- •progressive mCRPC.
- •have adequate organ function。
- •Subjects of childbearing potential voluntarily use an effective method of contraception, such as condoms, oral or injectable contraceptives, Intra-uterine device（IUD）,etc., during treatment and within 6 months of the last use of the trial drug.
排除标准
- •Previous treatment with any of the following within 6 months of enrollment: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation. Previous PSMA-targeted radioligand therapy is not allowed.
- •Known other malignancies.
- •Any systemic anti-cancer therapy (e.g. chemotherapy, immunotherapy or biological therapy within 28 days prior to day of enrollment.
- •Known hypersensitivity to the components of the study therapy or its analogs.
- •A superscan as seen in the baseline bone scan.
- •Patients with a history of Central Nervous System (CNS) metastases.
- •Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, cardiac arrhythmia, or other severe complications.
研究组 & 干预措施
225Ac-PSMA-XT treatment
Experimental
干预措施: 225Ac-PSMA-XT (Drug)
结局指标
主要结局
Treatment emergent adverse events
时间窗: Through study completion, assessed up to 2 years
To evaluate the safety and tolerability of \[177Lu\]Lu-PSMA-XT Injection assessed from the number and incidence of patients with adverse events using CTCAE v5.0 and physical examination, electrocardiogram and laboratory abnormality, etc.
Dose-limiting toxicity（DLT）
时间窗: Through study completion, assessed up to 2 years
Incidence and severity of dose-limiting toxicities.
次要结局
- Prostate-specific Antigen 50 (PSA50) Response(Through study completion, assessed up to 2 years.)
- Radiographic Progression-free Survival (rPFS)(Through study completion, assessed up to 2 years.)
- Overall Response Rate (ORR)(Through study completion, assessed up to 2 years.)
- Duration of Response (DOR)(Through study completion, assessed up to 2 years.)
- Disease Control Rate (DCR)(Through study completion, assessed up to 2 years.)
研究者
Xiaorong Sun
Director of Nuclear Medicine Department
Shandong Cancer Hospital and Institute
研究点 (1)
Loading locations...
相似试验
终止
1 期
A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate CancerMetastatic Castration-resistant Prostate CancerNCT04227275Tceleron Therapeutics, Inc.16
已完成
1 期
A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.TumorNCT05203601Shanghai Institute Of Biological Products36
招募中
早期 1 期
Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid TumorsNCT06577532Ruijin Hospital56
暂停
1 期
Phase I/II Study of APS001F With Flucytosine and Maltose in Solid TumorsTumorsNeoplasmsCancerNCT01562626Anaeropharma Science, Inc.75
已完成
1 期
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 AntigenAdvanced MalignanciesAdvanced CancerNCT04837196Astellas Pharma Global Development, Inc.24